The effect of adding low dose human Chorionic Gonadotropin (hCG) to recumbinant Follicular Stimulating Hormone (rFSH) on follicular phase in women undergoing intracytoplasmic sperm injection cycle, a clinical trial.

This research is done to examine the effect of adding low dose human Chorionic Gonadotropin (hCG) to recombinant Follicular Stimulating Hormone (rFSH) on follicular phase in women undergoing intracytoplasmic sperm injection cycle. This research is randomized double blind controlled clinical trial. Our trial performs in Fateme Zahra Reproductive Research Center in Babol, Iran. Patients with these inclusion criteria: 20 – 40 years old; normal salpingography are selected and randomly divided in three groups. Exclusion criteria include history of previous chronic disease. Patients randomly placed in to three groups of 50 women. In all three groups all patients treated with a dose of 150 International Unit (IU) rFSH per day. In the first group or control group treatment with rFSH will continue until the creation of the oocytes. In the second group when the follicle size become 14 millimeter, rFSH dose reduce to 75 IU per day and treatment starts with 100 IU hCG per day. In the third group when follicle size become 14 millimeter, treatment with rFSH stops and patient treat with 200 IU hCG per day. Gonadotropin administration continues to mature follicles. When at least two or three follicles 18 millimeter to 20 millimeter in size were formed; 100 IU hCG will inject. Thirty six hours later ovarian puncture is performed. Oocyte maturation, ovarian hyperstimulation syndrome and follicular response will compare in three groups.

Babol University of Medical Sciences.